Skip to main content

Market Overview

UPDATE: Barclays Capital Initiates Coverage On Biogen On Tecfidera Upside


In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Biogen Idec Inc (NASDAQ: BIIB) with an Overweight rating and $425.00 price target.

In the report, Barclays Capital noted, “Biogen's Tecfidera still offers a lot of upside in the multiple sclerosis (MS) market, especially in the EU, where it is early in the launch. Indeed, our EU forecasts are >$100M ahead of consensus for 2015-2017. In the pipeline, we think that phase 2 data for anti-LINGO in acute optic neuritis (AON) in 1Q15 should validate its mechanism based on our research. In turn, this may inject significant enthusiasm for the phase 2 in MS, though that is likely to be a 2016 data event. In the later stage pipeline, phase 3 data for Tysabri in SPMS is a 2H15 event; there are little to no expectations for this >$2.5B opportunity. Overall, we think that Biogen has the right combination of momentum from a healthy MS franchise and momentum from a diverse early to late stage pipeline. As a result, we're initiating coverage with an Overweight rating and $425 price target.”

Biogen closed on Monday at $336.74.

Latest Ratings for BIIB

Apr 2021WedbushMaintainsNeutral
Feb 2021Cantor FitzgeraldMaintainsNeutral
Feb 2021Credit SuisseMaintainsOutperform

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings


Related Articles (BIIB)

View Comments and Join the Discussion!

Posted-In: Barclays Capital Geoffrey MeachamAnalyst Color Initiation Analyst Ratings

Latest Ratings

GIKColliers SecuritiesInitiates Coverage On14.0
SANWLake StreetInitiates Coverage On6.0
LILAMorgan StanleyDowngrades15.0
BEJP MorganUpgrades36.0
NEXACredit SuisseUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at